A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia

JOURNAL ARTICLE published October 2016 in Investigational New Drugs

Authors: Karen W. L. Yee | Hsiao-Wei T. Chen | David W. Hedley | Sue Chow | Joseph Brandwein | Andre C. Schuh | Aaron D. Schimmer | Vikas Gupta | Deborah Sanfelice | Tara Johnson | Lisa W. Le | Jamie Arnott | Mark R. Bray | Carolyn Sidor | Mark D. Minden